More than skin deep: atherosclerosis as a systemic manifestation of psoriasis

被引:115
作者
Alexandroff, A. B. [1 ]
Pauriah, M. [2 ]
Camp, R. D. R. [3 ]
Lang, C. C. [2 ]
Struthers, A. D. [2 ]
Armstrong, D. J. [4 ]
机构
[1] Leicester Royal Infirm, Dept Dermatol, Leicester LE1 5WW, Leics, England
[2] Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Div Med & Therapeut, Dundee DD1 9SY, Scotland
[3] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England
[4] Altnagelvin Hosp, Dept Rheumatol, Londonderry, North Ireland
关键词
atherosclerosis; cardiovascular disease; metabolic syndrome; psoriasis; tumour necrosis factor-alpha; NECROSIS-FACTOR-ALPHA; REGULATORY T-CELLS; CORONARY-ARTERY-DISEASE; EVIDENT CARDIOVASCULAR-DISEASE; PLACEBO-CONTROLLED TRIAL; TOLL-LIKE-RECEPTORS; RHEUMATOID-ARTHRITIS; RISK-FACTORS; MYOCARDIAL-INFARCTION; ENDOTHELIAL FUNCTION;
D O I
10.1111/j.1365-2133.2009.09281.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
There is now growing evidence that psoriasis, like other inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus, is a systemic disorder that is associated with enhanced atherosclerosis and risk of coronary artery disease. Here we summarize the available epidemiological evidence for this association and analyse pathogenic features that are common to psoriasis and atherosclerosis. Further prospective studies are urgently needed to extend knowledge of the risk of cardiovascular morbidity and mortality in patients with psoriasis and to confirm the degree to which treatment of psoriasis reduces this risk. Nevertheless, existing data are sufficient to indicate that severe psoriasis should be more widely recognized as a potential risk factor for cardiovascular disease and should be considered with the established factors when formulating strategies for the management of cardiovascular risk.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 126 条
[1]   Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction [J].
Al Suwaidi, J ;
Hamasaki, S ;
Higano, ST ;
Nishimura, RA ;
Holmes, DR ;
Lerman, A .
CIRCULATION, 2000, 101 (09) :948-954
[2]   Detection of psoriasin/S100A7 in the sera of patients with psoriasis [J].
Anderson, K. S. ;
Wong, J. ;
Polyak, K. ;
Aronzon, D. ;
EnerbAck, C. .
BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (02) :325-332
[3]   Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? [J].
Andreakos, E ;
Foxwell, B ;
Feldmann, M .
IMMUNOLOGICAL REVIEWS, 2004, 202 :250-265
[4]   The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations:: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients [J].
Austin, LM ;
Ozawa, M ;
Kikuchi, T ;
Walters, IB ;
Krueger, JG .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) :752-759
[5]   Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis [J].
Baker, BS ;
Ovigne, JM ;
Powles, AV ;
Corcoran, S ;
Fry, L .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (04) :670-679
[6]   FOXP3+ regulatory T cells:: Current controversies and future perspectives [J].
Banham, Alison H. ;
Powrie, Fiona M. ;
Suri-Payer, Elisabeth .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2006, 36 (11) :2832-2836
[7]  
Benson J, 2008, BRIT J DERMATOL, V159, P1423
[8]   The use of ciclosporin in psoriasis [J].
Berth-Jones, J .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2005, 16 (5-6) :258-277
[9]   The pathogenic role of tissue-resident immune cells in psoriasis [J].
Boyman, Onur ;
Conrad, Curdin ;
Tonel, Giulia ;
Gilliet, Michel ;
Nestle, Frank O. .
TRENDS IN IMMUNOLOGY, 2007, 28 (02) :51-57
[10]   Psoriasis and the risk of incident diabetes mellitus: a population-based study [J].
Brauchli, Y. B. ;
Jick, S. S. ;
Meier, C. R. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (06) :1331-1337